<p>根據最近向證券交易委員會（SEC）提交的 13F 文件，Banque Transatlantique SA 在第三季度將其在愛德華生命科學公司（NYSE:EW - 免費報告）的持股比例削減了 32.6%。該機構投資者在季度內出售了 18,134 股後，持有 37,434 股該醫療研究公司的股票。Banque Transatlantique SA 在愛德華生命科學的持股在最近的報告期末價值為 2,907,000 美元。</p>
<p>獲取 <strong>愛德華生命科學</strong> 的提醒：</p>
<ul>
<li>深入分析醫療行業收益：AZN vs. EW vs. ZBH</li>
</ul>
<p>其他對沖基金也買賣了該公司的股票。Fjarde AP Fonden Fourth Swedish National Pension Fund 在第三季度將其在愛德華生命科學的持股增加了 7.0%。Fjarde AP Fonden Fourth Swedish National Pension Fund 現在擁有 137,835 股該醫療研究公司的股票，價值 10,719,000 美元，此前在上個季度額外購買了 9,069 股。Mirae Asset Global Investments Co. Ltd.在第三季度將其在愛德華生命科學的持股增加了 13.2%。Mirae Asset Global Investments Co. Ltd.現在擁有 86,235 股該醫療研究公司的股票，價值 6,706,000 美元，此前在上個季度額外購買了 10,078 股。Atlantic Union Bankshares Corp 在第三季度將其在愛德華生命科學的持股增加了 2,240.9%。Atlantic Union Bankshares Corp 現在擁有 11,892 股該醫療研究公司的股票，價值 925,000 美元，此前在上個季度額外購買了 11,384 股。OMERS ADMINISTRATION Corp 在第二季度將其在愛德華生命科學的持股增加了 97.3%。OMERS ADMINISTRATION Corp 現在擁有 44,504 股該醫療研究公司的股票，價值 3,481,000 美元，此前在上個季度額外購買了 21,950 股。最後，紐約梅隆銀行在第三季度將其在愛德華生命科學的持股增加了 8.1%。紐約梅隆銀行現在擁有 19,010,227 股該醫療研究公司的股票，價值 1,478,425,000 美元，此前在上個季度額外購買了 1,423,365 股。79.46% 的股票由機構投資者持有。</p>
<h2>愛德華生命科學股票下跌 3.3%</h2>
<p>NYSE:EW 的股票在週五開盤價為 81.82 美元。該公司的市值為 475.2 億美元，市盈率為 44.71，市盈率/增長比率為 2.21，貝塔值為 0.93。愛德華生命科學公司的 12 個月低點為 65.94 美元，12 個月高點為 87.89 美元。該公司的 50 日簡單移動平均線為 82.41 美元，200 日簡單移動平均線為 81.58 美元。公司快速比率為 3.09，流動比率為 3.72，債務與股本比率為 0.06。</p>
<ul>
<li>超越生物技術——3 只適合成長型投資者的醫療股票</li>
</ul>
<p>愛德華生命科學（NYSE:EW - 獲取免費報告）最近在 2 月 10 日（星期二）發佈了季度財報。該醫療研究公司報告季度每股收益為 0.58 美元，低於分析師一致預期的 0.62 美元，差距為 0.04 美元。該公司在季度內的收入為 15.7 億美元，而分析師預期為 15.4 億美元。愛德華生命科學的股本回報率為 14.50%，淨利潤率為 17.69%。與去年同期相比，愛德華生命科學的收入增長了 13.3%。在去年同期，該公司每股收益為 0.59 美元。愛德華生命科學已將其 2026 年第一季度的指導目標設定為 0.700-0.760 美元每股收益。分析師預測愛德華生命科學公司今年的每股收益將達到 2.45 美元。</p>
<h2>內部人士買賣情況</h2>
<p>在其他新聞中，副總裁 Daniel J. Lippis 在 3 月 11 日（星期三）出售了 1,019 股公司的股票。該股票以平均 85.38 美元的價格出售，總價值為 87,002.22 美元。交易後，副總裁直接持有 33,934 股公司的股票，價值為 2,897,284.92 美元。此次交易使其持股減少了 2.92%。該出售在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。此外，副總裁 Donald E. Bobo, Jr.在 2 月 25 日（星期三）出售了 24,000 股公司的股票。該股票以平均 83.84 美元的價格出售，總價值為 2,012,160.00 美元。出售後，副總裁在公司中持有 21,266 股，價值約為 1,782,941.44 美元。此次交易使其持股減少了 53.02%。有關此次出售的更多細節可在官方 SEC 披露中找到。內部人士在上個季度出售了 61,718 股公司股票，價值為 5,236,281 美元。內部人士持有公司股票的 1.29%。</p>
<h2>分析師設定新目標價</h2>
<ul>
<li>3 只具有長期順風的醫療行業開拓者</li>
</ul>
<p>EW 已成為多份研究分析師報告的主題。BTIG Research 在 2 月 11 日（星期三）重新發布了 “買入” 評級，並將愛德華生命科學的目標價設定為 103.00 美元。Robert W. Baird 在 1 月 12 日（星期一）設定了愛德華生命科學的目標價為 90.00 美元。花旗集團在 12 月 11 日（星期四）重新發布了 “買入” 評級，並將愛德華生命科學的目標價從 96.00 美元上調至 101.00 美元。TD Cowen 在 1 月 9 日（星期五）將愛德華生命科學的評級從 “持有” 上調至 “買入”。最後，摩根大通將愛德華生命科學的評級從 “中性” 上調至 “增持”，並將該股票的目標價從 90.00 美元上調至 100.00 美元。三位投資分析師對該股票給予了強烈買入評級，十五位給予了買入評級，九位給予了持有評級。根據 MarketBeat.com，該公司目前的平均評級為 “適度買入”，平均目標價為 96.14 美元。</p>
<p><strong>獲取我們對愛德華生命科學的最新分析</strong></p>
<h2>愛德華生命科學簡介</h2>
<p>（免費報告）</p>
<p>愛德華生命科學是一家醫療技術公司，專注於結構性心臟病和重症監護的產品和療法。該公司設計、開發和製造用於外科手術和微創（經導管）程序的心臟瓣膜及相關輸送系統。其產品組合涵蓋多種瓣膜疾病，重點是能夠進行經導管主動脈瓣置換（TAVR）作為開放心臟手術替代方案的技術。</p>
<p>除了經導管心臟瓣膜——包括廣為人知的 SAPIEN 系列——愛德華還提供外科組織瓣膜和心臟外科醫生、介入心臟病專家及醫院團隊使用的輔助設備。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們認為比愛德華生命科學更好的股票</li>
<li>馬丁·韋斯的個人警告（請閲讀）</li>
<li>SpaceX IPO 確認：今天就來認領你的股份</li>
<li>這枚硬幣擁有一切優勢</li>
<li>今天僅限 500 人……</li>
<li>華爾街害怕的黃金圖表……</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在愛德華生命科學嗎？</h2>
<p>在考慮愛德華生命科學之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而愛德華生命科學並不在名單上。</p>
<p>雖然愛德華生命科學目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

美國醫藥設備 ETF - iShares

標普健康醫療設備 ETF - SPDR

愛德華生命科學

<p>法蘭西跨大西洋銀行（Banque Transatlantique SA）在第三季度減少了對愛德華生命科學（Edwards Lifesciences Corporation，NYSE:EW）的持股比例，下降幅度為 32.6%，目前持有 37,434 股，市值為 291 萬美元。其他機構投資者也調整了他們的持倉，Fjarde AP Fonden 的持股增加了 7%，而大西洋聯合銀行（Atlantic Union Bankshares）的持倉則增加了 2,240.9%。最近，愛德華生命科學的股價下跌了 3.3%，市值為 475.2 億美元，市盈率為 44.71。該公司報告的收入同比增長了 13.3%，但在最近的季度財報中未能達到每股收益（EPS）預期</p>

<p>Banque Transatlantique SA trimmed its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 32.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,434 shares of the medical research company's stock after selling 18,134 shares during the quarter. Banque Transatlantique SA's holdings in Edwards Lifesciences were worth $2,907,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根據最近向證券交易委員會（SEC）提交的 13F 文件，Banque Transatlantique SA 在第三季度將其在愛德華生命科學公司（NYSE:EW - 免費報告）的持股比例削減了 32.6%。該機構投資者在季度內出售了 18,134 股後，持有 37,434 股該醫療研究公司的股票。Banque Transatlantique SA 在愛德華生命科學的持股在最近的報告期末價值為 2,907,000 美元。</p>
</div><p>Get <strong>Edwards Lifesciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>愛德華生命科學</strong> 的提醒：</p>
</div><ul>
<li>A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH</li>
</ul>
<div class="lb-trans"><ul>
<li>深入分析醫療行業收益：AZN vs. EW vs. ZBH</li>
</ul>
</div><p>Other hedge funds have also bought and sold shares of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company's stock worth $10,719,000 after buying an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Edwards Lifesciences by 13.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company's stock valued at $6,706,000 after acquiring an additional 10,078 shares during the last quarter. Atlantic Union Bankshares Corp raised its position in Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company's stock valued at $925,000 after purchasing an additional 11,384 shares in the last quarter. OMERS ADMINISTRATION Corp lifted its stake in Edwards Lifesciences by 97.3% during the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company's stock worth $3,481,000 after purchasing an additional 21,950 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company's stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares during the last quarter. 79.46% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他對沖基金也買賣了該公司的股票。Fjarde AP Fonden Fourth Swedish National Pension Fund 在第三季度將其在愛德華生命科學的持股增加了 7.0%。Fjarde AP Fonden Fourth Swedish National Pension Fund 現在擁有 137,835 股該醫療研究公司的股票，價值 10,719,000 美元，此前在上個季度額外購買了 9,069 股。Mirae Asset Global Investments Co. Ltd.在第三季度將其在愛德華生命科學的持股增加了 13.2%。Mirae Asset Global Investments Co. Ltd.現在擁有 86,235 股該醫療研究公司的股票，價值 6,706,000 美元，此前在上個季度額外購買了 10,078 股。Atlantic Union Bankshares Corp 在第三季度將其在愛德華生命科學的持股增加了 2,240.9%。Atlantic Union Bankshares Corp 現在擁有 11,892 股該醫療研究公司的股票，價值 925,000 美元，此前在上個季度額外購買了 11,384 股。OMERS ADMINISTRATION Corp 在第二季度將其在愛德華生命科學的持股增加了 97.3%。OMERS ADMINISTRATION Corp 現在擁有 44,504 股該醫療研究公司的股票，價值 3,481,000 美元，此前在上個季度額外購買了 21,950 股。最後，紐約梅隆銀行在第三季度將其在愛德華生命科學的持股增加了 8.1%。紐約梅隆銀行現在擁有 19,010,227 股該醫療研究公司的股票，價值 1,478,425,000 美元，此前在上個季度額外購買了 1,423,365 股。79.46% 的股票由機構投資者持有。</p>
</div><h2>Edwards Lifesciences Stock Down 3.3%</h2>
<div class="lb-trans"><h2>愛德華生命科學股票下跌 3.3%</h2>
</div><p>Shares of NYSE:EW opened at $81.82 on Friday. The firm has a market cap of $47.52 billion, a P/E ratio of 44.71, a P/E/G ratio of 2.21 and a beta of 0.93. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The business has a fifty day simple moving average of $82.41 and a 200 day simple moving average of $81.58. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06.</p>
<div class="lb-trans"><p>NYSE:EW 的股票在週五開盤價為 81.82 美元。該公司的市值為 475.2 億美元，市盈率為 44.71，市盈率/增長比率為 2.21，貝塔值為 0.93。愛德華生命科學公司的 12 個月低點為 65.94 美元，12 個月高點為 87.89 美元。該公司的 50 日簡單移動平均線為 82.41 美元，200 日簡單移動平均線為 81.58 美元。公司快速比率為 3.09，流動比率為 3.72，債務與股本比率為 0.06。</p>
</div><ul>
<li>Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>超越生物技術——3 只適合成長型投資者的醫療股票</li>
</ul>
</div><p>Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts' consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences's revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.</p>
<div class="lb-trans"><p>愛德華生命科學（NYSE:EW - 獲取免費報告）最近在 2 月 10 日（星期二）發佈了季度財報。該醫療研究公司報告季度每股收益為 0.58 美元，低於分析師一致預期的 0.62 美元，差距為 0.04 美元。該公司在季度內的收入為 15.7 億美元，而分析師預期為 15.4 億美元。愛德華生命科學的股本回報率為 14.50%，淨利潤率為 17.69%。與去年同期相比，愛德華生命科學的收入增長了 13.3%。在去年同期，該公司每股收益為 0.59 美元。愛德華生命科學已將其 2026 年第一季度的指導目標設定為 0.700-0.760 美元每股收益。分析師預測愛德華生命科學公司今年的每股收益將達到 2.45 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣情況</h2>
</div><p>In other news, VP Daniel J. Lippis sold 1,019 shares of the business's stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares of the company's stock, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the company's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the sale, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,718 shares of company stock valued at $5,236,281 over the last quarter. Insiders own 1.29% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，副總裁 Daniel J. Lippis 在 3 月 11 日（星期三）出售了 1,019 股公司的股票。該股票以平均 85.38 美元的價格出售，總價值為 87,002.22 美元。交易後，副總裁直接持有 33,934 股公司的股票，價值為 2,897,284.92 美元。此次交易使其持股減少了 2.92%。該出售在向證券交易委員會提交的文件中披露，文件可通過此鏈接獲取。此外，副總裁 Donald E. Bobo, Jr.在 2 月 25 日（星期三）出售了 24,000 股公司的股票。該股票以平均 83.84 美元的價格出售，總價值為 2,012,160.00 美元。出售後，副總裁在公司中持有 21,266 股，價值約為 1,782,941.44 美元。此次交易使其持股減少了 53.02%。有關此次出售的更多細節可在官方 SEC 披露中找到。內部人士在上個季度出售了 61,718 股公司股票，價值為 5,236,281 美元。內部人士持有公司股票的 1.29%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><ul>
<li>3 Healthcare Pathbreakers With Long-Term Tailwinds</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只具有長期順風的醫療行業開拓者</li>
</ul>
</div><p>EW has been the subject of a number of research analyst reports. BTIG Research reissued a &#34;buy&#34; rating and set a $103.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research note on Monday, January 12th. Citigroup reissued a &#34;buy&#34; rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. TD Cowen raised shares of Edwards Lifesciences from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Friday, January 9th. Finally, JPMorgan Chase &amp; Co. upgraded shares of Edwards Lifesciences from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and upped their price objective for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $96.14.</p>
<div class="lb-trans"><p>EW 已成為多份研究分析師報告的主題。BTIG Research 在 2 月 11 日（星期三）重新發布了 “買入” 評級，並將愛德華生命科學的目標價設定為 103.00 美元。Robert W. Baird 在 1 月 12 日（星期一）設定了愛德華生命科學的目標價為 90.00 美元。花旗集團在 12 月 11 日（星期四）重新發布了 “買入” 評級，並將愛德華生命科學的目標價從 96.00 美元上調至 101.00 美元。TD Cowen 在 1 月 9 日（星期五）將愛德華生命科學的評級從 “持有” 上調至 “買入”。最後，摩根大通將愛德華生命科學的評級從 “中性” 上調至 “增持”，並將該股票的目標價從 90.00 美元上調至 100.00 美元。三位投資分析師對該股票給予了強烈買入評級，十五位給予了買入評級，九位給予了持有評級。根據 MarketBeat.com，該公司目前的平均評級為 “適度買入”，平均目標價為 96.14 美元。</p>
</div><p><strong>Get Our Latest Analysis on Edwards Lifesciences</strong></p>
<div class="lb-trans"><p><strong>獲取我們對愛德華生命科學的最新分析</strong></p>
</div><h2>Edwards Lifesciences Profile</h2>
<div class="lb-trans"><h2>愛德華生命科學簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.</p>
<div class="lb-trans"><p>愛德華生命科學是一家醫療技術公司，專注於結構性心臟病和重症監護的產品和療法。該公司設計、開發和製造用於外科手術和微創（經導管）程序的心臟瓣膜及相關輸送系統。其產品組合涵蓋多種瓣膜疾病，重點是能夠進行經導管主動脈瓣置換（TAVR）作為開放心臟手術替代方案的技術。</p>
</div><p>In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.</p>
<div class="lb-trans"><p>除了經導管心臟瓣膜——包括廣為人知的 SAPIEN 系列——愛德華還提供外科組織瓣膜和心臟外科醫生、介入心臟病專家及醫院團隊使用的輔助設備。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Edwards Lifesciences</li>
<li>A personal warning from Martin Weiss (Please read)</li>
<li>SpaceX IPO Confirmed: Claim Your Stake Today</li>
<li>This coin has everything going for it</li>
<li>Only 500 people today…</li>
<li>The gold chart Wall Street is terrified of…</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比愛德華生命科學更好的股票</li>
<li>馬丁·韋斯的個人警告（請閲讀）</li>
<li>SpaceX IPO 確認：今天就來認領你的股份</li>
<li>這枚硬幣擁有一切優勢</li>
<li>今天僅限 500 人……</li>
<li>華爾街害怕的黃金圖表……</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=EW"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Edwards Lifesciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在愛德華生命科學嗎？</h2>
</div><p>Before you consider Edwards Lifesciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮愛德華生命科學之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而愛德華生命科學並不在名單上。</p>
</div><p>While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然愛德華生命科學目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Banque Transatlantique SA 在愛德華生命科學公司持有 291 萬美元的股份